Lymphoma :: BiovaxID – Promising for Follicular Lymphoma

According to results recently presented at the 47th annual meeting of the American Society of Hematology (ASH), the vaccine BiovaxID, which is still in clinical trials, appears very promising in the treatment of follicular lymphoma.

Researchers recently completed long-term follow-up of a clinical trial evaluating BiovaxID in the treatment of follicular lymphoma. This trial included patients who had received prior chemotherapy referred to as PACE chemotherapy. Patients were in remission (no detectable cancer cells) following PACE for six months. They were then treated with a series of BiovaxID injections.

The researchers concluded that these long-term results are very encouraging for the use of BiovaxID in the treatment of follicular lymphoma. A phase III trial, the last phase prior to FDA review, is currently ongoing and enrolling patients. Patients diagnosed with follicular lymphoma may wish to speak with their physician regarding their individual risks and benefits of participating in a clinical trial further evaluating BiovaxID or other novel therapeutic approaches.


Leave a Comment